Popova NA, Nikolin VP, Kaledin VI, Serova IA, Matyunina EA, Bakarev MA, Lushnikova EL, Vologodskii AN. Experimental Study of Antitumor Activity of Pefagtal Addressed to αvβ3 Integrins.
Bull Exp Biol Med 2022;
173:105-109. [PMID:
35618966 DOI:
10.1007/s10517-022-05502-6]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Indexed: 11/30/2022]
Abstract
We studied the effect of a new targeted drug Pefagtal that represents a conjugate in which the MS2 phage filled with a substance toxic to cells (thallium salts) is covalently linked to peptides containing the RGD motif. The antitumor and pronounced antimetastatic effects of Pefagtal were demonstrated on transplanted mouse tumors differing in histological type and status of metastasis: Krebs-2 ascites adenocarcinoma of the mammary gland, Lewis lung adenocarcinoma, hepatoma-29, and lung adenocarcinoma. It is assumed that the RGD motif mediates primary binding of the construct to αvβ3 and αvβ5 integrins that are predominantly overexpressed in the endothelial cells of tumor blood vessels and in tumor and metastatic cells.
Collapse